Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexlansoprazole MR in Non-Erosive GERD
NCT00251745Phase 3Completed
- Sponsor
- Takeda
- Start
- Dec 2005
- Primary completion
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexlansoprazole in gastroesophageal reflux disease (GERD) (3 arms), sponsored by Takeda. Primary endpoint: Percentage of Days With Neither Daytime Nor Nighttime Heartburn at 4 weeks. Started Dec 2005; status: completed.
02
Drugs
dexlansoprazole
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT00251745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00251745.